Shigenori E. Nagai - Concepedia

Author

Shigenori E. Nagai

Also Known As

Nagai,Shigenori E., S Nagai, S. E. Nagai, S. Nagai, SHIGENORI E. NAGAI, Shigenori E Nagai, Shigenori E. Nagai, Shigenori Nagai

Publications

789

Citations

H-Index

Concepts

All Affiliations

Saitama Cancer Center Aichi Cancer Center National Cancer Center Hospital East The Cancer Institute Hospital Kyoto University

About

Shigenori E. Nagai is an author at Saitama Cancer Center specializing in breast cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	321
2	Health Sciences	2	2	51
3	Nursing	2	2	121
4	Public Health	1	1	33
5	Global Health	1	1	33

Shigenori E. Nagai

Publications

693

Citations

H-Index

Page 1

	Year	Citations
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients Yasuhiro Fujiwara, Hirofumi Mukai, Toshiaki Saeki, British Journal of Cancer	2019	123
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition Tomohiko Aihara, Tatsuya Toyama, Masato Takahashi, Breast Cancer NursingSurgical OncologyBreast OncologyMedicineCancer Management	2016	88
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition Tatsunori Shimoi, Shigenori E. Nagai, Tetsuhiro Yoshinami, Breast Cancer	2020	75
Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer Yuji Hayashi, Hiroyuki Takei, Satoshi Nozu, Oncology Letters Pathological Tumor ResponsesBreast OncologyNeoadjuvant ChemotherapyMedicinePathology	2012	65
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition Mitsuo Terada, Aki Ito, Yuichiro Kikawa, Breast Cancer	2023	53
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer José Baselga, Claudio Zamagni, Patricia Gómez, Clinical Breast Cancer Breast OncologyOncologyMedicineLocally AdvancedClinical Trials	2017	46
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) Masahiro Takada, Hiroshi Ishiguro, Shigenori E. Nagai, Breast Cancer Research and Treatment Breast OncologyOncologyBreast CancerJbcrg-c03 StudyCancer Treatment	2014	37
Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan Maarten J. Fischer, Kenichi Inoue, Ayako Matsuda, Breast Cancer Research and Treatment NursingQuality Of LifeBreast Cancer PatientsSocial HealthGlobal Health	2017	33
Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study Atsumori Hamahata, Kazuyuki Kubo, Hiroyuki Takei, Breast Cancer Surgical OncologyBreast OncologyMedicineCancer ManagementBreast Cancer	2013	26
Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies Hiroyuki Takei, Masafumi Kurosumi, Takashi Yoshida, Breast Cancer Surgical OncologyBreast OncologyMedicineSurgical PathologyBreast Cancer	2009	23

Page 1